Abstract
In this open-label trial, ten male patients with active Behcet’s uveitis were enrolled. Initially, two infliximab infusions (5 mg/kg) were given at weeks 0 and 2. The patients continued to receive conventional therapy on recurrence of severe uveitis (RSU) attack. The patients with further attack were regularly given infliximab infusions every 8 weeks. In cases of further RSU attacks, the infusion interval was reduced to 6 weeks. The total follow-up period was 3 years. The patients were monitored for RSU, visual acuity and adverse effects. Reduction in the doses of prednisolone was also monitored. After receiving two infliximab infusions at weeks 0 and 2, three patients remained attack-free and seven patients had another RSU attack between 8th and 47th week. These patients were regularly given infliximab at 8-week intervals. Five out of seven patients remained attack-free. In two patients who had further attack, infusion frequency was increased to 6 weeks. There was a remarkable improvement in visual acuity with no significant adverse reaction except mild respiratory tract infection (two patients), headache (one patient) and mild infusion reaction (one patient). Infliximab is a safe and effective drug for the management of Behcet’s uveitis. Selection of optimal dose and frequency of infusion required standardization for individual patient.
Similar content being viewed by others
References
International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080
Tugal-Tutkun J, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behcet’s disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380
Atmaca LS, Batioglu F (1994) The efficacy of cyclosporine-A in the treatment of Behcet’s disease. Ophthalmic Surg 25:321–327
Ozdal PC, Ortac S, Taskintuna I, Firat E (2002) Long-term therapy with low dose cyclosporine A in ocular Behcet’s disease. Doc Ophthalmol 105:301–312
Kaklamani VG, Kaklamani PG (2001) Treatment of Behcet’s disease: an update. Semin Arthritis Rheum 30:299–312
Hamzaoui K, Hamza M, Ayed K (1990) Production of TNF-alpha and IL-1 in active Behcet’s disease. J Rheumatol 17:1428–1429
Santos LM, Marcos MC, Gallardo Galera JM (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251–255
Gul A (2001) Behcet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 19(Suppl 24):S6–S12
Maini SR (2004) Infliximab treatment of rheumatoid arthritis. Rheum Dis Clin North Am 30:329–347
Rutgeerts P, van Assche G, Vermeire S (2004) Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126:1593–1610
Braun J, Sieper J (2004) Biological therapies in the spondyloarthritides: the current state. Rheumatology (Oxford) 43:1072–1084
Haugeberg G, Velken M, Johnsen V (2000) Successful treatment of genital ulcers with infliximab in Behcet’s disease. Ann Rheum Dis 63:744–745
Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gul A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum 52:2478–2484
Andonopoulos AP, Meimaris N, Daoussis D et al (2003) Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behcet’s disease. Clin Exp Rheumatol 21(Suppl 30):S57–S58
Kram MT, May LD, Goodman S, Molinas S (2003) Behcet’s Ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 46:118–121
Sfikakis PP, Kaklamanis PH, Elezoglou A et al (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet’s disease. Ann Intern Med 140:404–406
Nakamura S, Ohno S (2005) Anti-tumor necrosis factor alpha antibody in the treatment of Behcet’s disease. Int Ophthalmol Clin 45:179–189
Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet 358:295–296
Kaklamani VG, Kaklamanis PG (2001) Treatment of Behcet’s disease: an update. Semin Arthritis Rheum 30:299–312
Carmaschi P, Biasi D, Lombathi M et al (2006) Anti-TNF therapy in rheumatoid arthritis and autoimmunity. Rheum Int 26:209–214
Comby E, Tanaff P, Mariotte D et al (2006) Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with long term infliximab therapy. J Rheum 33:24–30
Louis M, Rauch J, Armstrong M, Fitzcharles MA (2003) Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 30:2557–2562
Weill B, Kahan A (2004) Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 22:756–758
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Al-Rayes, H., Al-Swailem, R., Al-Balawi, M. et al. Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial. Rheumatol Int 29, 53–57 (2008). https://doi.org/10.1007/s00296-008-0606-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-008-0606-8